• June 3-6, 2024
  • San Diego Convention Center, California


Peter de Haan

Peter de Haan, PhD

Founder and Chief Scientific Officer
Amarna Therapeutics BV
Peter has a biology background and has been active in R&D for 35 years. Peter’s academic career started as a Virologist at the Wageningen University in The Netherlands, where he obtained his PhD in 1991. In 1991 he joined Novartis Seeds where he held several research management positions in the field of plant biotechnology. He is a co-founder of Viruvation B.V., which was active in developing a therapeutic AIDS vaccine. In 2008 Peter founded Amarna Therapeutics BV, a Gene and Immunotherapy company dedicated to the development of gene replacement and tolerization therapies for congenital and idiopathic diseases including hemophilia, type 1 diabetes mellitus, multiple sclerosis and age-related macular degeneration. Amarna has developed a proprietary viral gene delivery vector platform based on the macaque polyomavirus SV40. Peter is the (co-) author of more than 50 peer reviewed scientific articles and (co-) inventor of more than 15 different awarded patent families and patent applications.
Speaking In


Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.